New York Times Bio On Martin Shkreli Weighs On KaloBios Pharma Stock

KaloBios Pharmaceuticals Inc KBIO shares are trading lower by $1.20 at $29.93 in Monday's session. A not-so-favorable article in Sunday's New York Times business section might have investors reevaluating Martin Shkreli's business tactics. The issue peaked shortly after the open at $32.85 and the ensuing decline has found support ahead of Wednesday's low ($28.02) at $29.51.